Paris, 23 September 2014 - Neovacs (Alternext Paris: ALNEV, FR0004032746), a leader in active immunotherapies for the treatment of autoimmune diseases, will return to the “Healthcare & Biotechnology Conference” organized by Société Générale on Wednesday, 24 September.
Miguel Sieler, Neovacs’ CEO, will meet with investors to explain the innovative Kinoid technology, the current status of clinical developments, the outlook for its pre-clinical portfolio and the company’s strategy for the future.
“We are very happy and flattered to be invited to this prestigious event, which enables us to meet major investors fully knowledgeable about the biotech field and capable of appreciating the risks and opportunities offered by sector companies,” explains Miguel Sieler before adding: “Our attendance at this event is the natural continuation of the investor meetings we have held since May as part of our roadshow, which included Frankfort, Munich, Amsterdam and Hong Kong, as well as New York last June as part of French Biotech Day organised by France Biotech.”
About Neovacs
Neovacs is a biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by six patent families that run until at least 2023) Neovacs is focusing its development efforts on two active immunotherapies: TNF-Kinoid is being developed for the treatment of TNF-mediated autoimmune diseases such as rheumatoid arthritis and Crohn’s disease, whereas IFNa-Kinoid is being developed for the indication of lupus. Neovacs is also conducting preclinical works on IFNa-Kinoid in certain chronic viral infections, VEGF-Kinoid in Age-related Macular Degeneration (AMD) and solid tumors, and IL-4-Kinoid for the treatment of allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.
For more information on Neovacs, visit www.neovacs.fr
Press & Financial Communication France - Publicis
Stéphanie Tabouis
+33 (0) 1 44 82 46 35
stéphanie.tabouis@consultants.publicis.fr
Aubane de Gélis
+33 (0) 1 44 82 46 38
aubane.de-gelis@consultants.publicis.fr
Help employers find you! Check out all the jobs and post your resume.
